A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas

Predictors of acute adverse events from rapid rituximab infusion

(2013) Dora S. P. Lang et al.   SUPPORTIVE CARE IN CANCER

Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma

(2012) Junshik Hong et al.   SUPPORTIVE CARE IN CANCER

Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens

(2011) Naoe Goto et al.   ANNALS OF HEMATOLOGY

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

(2011) E. Campo et al.   BLOOD

An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma

(2011) Katsuhiro Miura et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study

(2008) Lee S. Schwartzberg et al.   SUPPORTIVE CARE IN CANCER